Results 41 to 50 of about 27,201 (202)

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer

BMC Cancer, 2021
Background Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. Human epidermal growth factor receptor 2 (HER2) amplification occurs in approximately 13–23% of all GC cases and patients with HER2 overexpression exhibit a ...
Gang Ning, Qihui Zhu, Wonyoung Kang, Hamin Lee, Leigh Maher, Yun-Suhk Suh, Michael Michaud, Mayerlin Silva, Jee Young Kwon, Chengsheng Zhang, Charles Lee   +10 more
doaj   +1 more source

A Systematic Intracranial Exposure‐Response Evaluation of Brain‐Penetrant Inhibitors: Informing Dose Selection for Brain Metastases [PDF]

Clin Transl Sci
ABSTRACT Brain metastases (BMs) represent a major clinical challenge due to their high incidence in cancers such as non‐small cell lung cancer (NSCLC) and breast cancer, and the limited efficacy of systemic therapies resulting from inadequate drug penetration across the blood–brain barrier.
Zhao Y, Huang W.
europepmc   +2 more sources

Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer

Medicinal Research Reviews, EarlyView.
ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek, Jernej Cingl, Urša Pečar Fonović, Tihomir Tomašič   +3 more
wiley   +1 more source

Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation [version 1] [PDF]

, 2019
Chemoresistance is an obstacle to the successful treatment of nasopharyngeal carcinoma (NPC). To explore novel treatment strategies, we first characterized the lapatinib-sensitivity of a panel of NPC cell lines by SRB and clonogenic cytotoxic assays and ...
Aimjongjun, Sathid, Yague, Ernesto, Yao, Shang, Janvilisri, Tavan, Lam, Eric W-F, Alasiri, Glowi, Mahmud, Zimam, Jiramongkol, Yannasittha   +7 more
core   +1 more source

Clinical data mining reveals analgesic effects of lapatinib in cancer patients

Scientific Reports, 2021
Microsomal prostaglandin E2 synthase 1 (mPGES-1) is recognized as a promising target for a next generation of anti-inflammatory drugs that are not expected to have the side effects of currently available anti-inflammatory drugs.
Shuo Zhou, Fang Zheng, Chang-Guo Zhan
doaj   +1 more source

The efficacy of concurrent chemoradiotherapy with or without nimotuzumab in high‐risk patients with locally advanced head and neck squamous cell carcinoma post‐surgery: A real‐world study

Precision Radiation Oncology, EarlyView.
Figure 1 Patient selection flowchart. CCRT, concurrent chemoradiotherapy; NCCRT, nimotuzumab and concurrent chemoradiotherapy. Abstract Purpose Patients with locally advanced head and neck squamous cell carcinoma (LA‐HNSCC) harboring high‐risk pathological features after radical surgery face high recurrence rates.
Yuejia Zhou, Linting Zhang, Wenjuan Lai, Jingyun Tan, Jing Gao, Yajie Liu, Shubin Wang, Feng Peng, Gangling Tong   +8 more
wiley   +1 more source

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source

Lapatinib in the Treatment of Breast Cancer

, 2009
Lapatinib is an oral dual tyrosine kinase inhibitor against epidermal growth factor receptor (EGFR) and HER-2/ neu (HER2). The success of trastuzumab in breast cancer prompted investigations of lapatinib in breast cancer, which revealed that lapatinib ...
Hideko Yamauchi, Tiffany LaFortune, Naoto T. Ueno   +2 more
core   +1 more source

Epigenetic control of cellular plasticity in breast cancer progression

The FEBS Journal, EarlyView.
Cancer cells undergo cell state transitions, termed plasticity, driving cancer progression and dictating therapeutic response. We define breast cancer plasticity into four interconnected processes: (1) breast cancer stem cell fates, (2) epithelial‐to‐mesenchymal transition, (3) maintenance of luminal identity, and (4) acquisition of therapeutic ...
Ellie J. Massey, Elizabeth Podleszanski, William J. Muller   +2 more
wiley   +1 more source